You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Polatuzumab vedotin

Showing 1 - 25 of 275
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Post-transplant Lymphoproliferative Disorder Trial in Saint Louis (Polatuzumab vedotin, Rituximab, CHP)

Not yet recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Polatuzumab vedotin
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 9, 2023

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)

Not yet recruiting
  • Large B-Cell Lymphoma
  • Xi'an, China
    First Affiliated Hospital of Medical College of Xi'an Jiaotong U
Sep 14, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Lymphoma, Follicular, Follicular Lymphoma Trial in Saint Louis (Mosunetuzumab, Polatuzumab vedotin)

Recruiting
  • Lymphoma, Follicular
  • Follicular Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 14, 2022

Richter Syndrome, Chronic Lymphocytic Leukemia Trial in New York (Polatuzumab Vedotin, Rituximab, Etoposide)

Recruiting
  • Richter Syndrome
  • Chronic Lymphocytic Leukemia
  • Polatuzumab Vedotin
  • +5 more
  • New York, New York
    Weill Cornell Medicine
Dec 19, 2022

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Polatuzumab vedotin (PV)
  • +6 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Aug 9, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Austria, Germany (Glofitamab, Rituximab, Obinutuzumab)

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Linz, Austria
  • +17 more
Mar 22, 2023

Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 7, 2022

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)

Not yet recruiting
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Boston, Massachusetts
  • +1 more
Apr 4, 2023

DLBCL, Lymphoma, B-Cell Trial in Rochester (Polatuzumab vedotin, Rituximab, Cyclophosphamide)

Recruiting
  • DLBCL
  • Lymphoma, B-Cell
  • Polatuzumab vedotin
  • +4 more
  • Rochester, New York
    University of Rochester
Jan 6, 2022

Diffuse, Large B-Cell, Lymphoma Trial in China (Polatuzumab Vedotin, Bendamustine, Rituximab)

Completed
Has Results
  • Diffuse, Large B-Cell, Lymphoma
  • Polatuzumab Vedotin
  • +3 more
  • Beijing, China
  • +9 more
Jul 7, 2022

Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial in Miami (Mosunetuzumab,

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +2 more
  • Miami, Florida
    University of Miami
Aug 3, 2022

Non-Hodgkin's Lymphoma Trial in Australia, Italy, United States (Obinutuzumab, Rituximab, Polatuzumab Vedotin)

Completed
  • Non-Hodgkin's Lymphoma
  • Tucson, Arizona
  • +22 more
Aug 5, 2022

Diffuse Large B Cell Lymphoma Trial (Polatuzumab Vedotin)

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
May 3, 2022

B-cell Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin)

Recruiting
  • B-cell Non-Hodgkin Lymphoma
  • Mosunetuzumab (IV)
  • +4 more
  • Birmingham, Alabama
  • +28 more
Jan 6, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Non-Hodgkins Lymphoma Trial in Worldwide (Glofitamab, Atezolizumab, Obinutuzumab)

Recruiting
  • Non-Hodgkins Lymphoma
  • Charlotte, North Carolina
  • +21 more
Jan 18, 2023

Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab, Polatuzumab vedotin, Tocilizumab)

Recruiting
  • Non-Hodgkin Lymphoma
  • Buenos Aires, Argentina
  • +18 more
Aug 10, 2022

B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma Trial in Valhalla (Polatuzumab vedotin)

Recruiting
  • B-cell Lymphoma
  • +8 more
  • Polatuzumab vedotin
  • Valhalla, New York
    New York Medical Center
Oct 29, 2021